ArticleVaccine2023
The impact of disruptions caused by the COVID-19 pandemic on global polio eradication.
Article in Vaccine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.
- Review of Poliovirus Transmission and Economic Modeling to Support Global Polio Eradication: 2020-2024.Pathogens (Basel, Switzerland) · 2024Pooled it
- Quantifying the benefits of improved operations for polio outbreak response: A model-based analysis.Vaccine · 2026Article
- Impediments to Progress Toward Polio Eradication During 2014-2024: Effectively Addressing the Current Challenges.Vaccines · 2025Review
- Advances and challenges in poliomyelitis vaccines: a comprehensive review of development, production, and global deployment.Frontiers in public health · 2025Review
- Characterization of environmental and clinical surveillance inputs to support prospective integrated modeling of the polio endgame.PLOS global public health · 2025Review
- Increasing Population Immunity Prior to Globally-Coordinated Cessation of Bivalent Oral Poliovirus Vaccine (bOPV).Pathogens (Basel, Switzerland) · 2024Article
- Modeling the spread of circulating vaccine-derived poliovirus type 2 outbreaks and interventions: A case study of Nigeria.Vaccine: X · 2024Article
- Estimating the health effects of COVID-19-related immunisation disruptions in 112 countries during 2020-30: a modelling study.The Lancet. Global health · 2024Article
- Worst-case scenarios: Modeling uncontrolled type 2 polio transmission.Risk analysis : an official publication of the Society for Risk Analysis · 2024Article
- Coordinated global cessation of oral poliovirus vaccine use: Options and potential consequences.Risk analysis : an official publication of the Society for Risk Analysis · 2024Review
- Impact of pandemics and disruptions to vaccination on infectious diseases epidemiology past and present.Human vaccines & immunotherapeutics · 2023Review
- COVID-19 retreats and world recovers: A silver lining in the dark cloud.Health care science · 2023Review
- Article
- The immediate impact of the COVID-19 pandemic on polio immunization and surveillance activities.Vaccine · 2023Review
- Serotype 2 oral poliovirus vaccine (OPV2) choices and the consequences of delaying outbreak response.Vaccine · 2023Article
- Modeling scenarios for ending poliovirus transmission in Pakistan and Afghanistan.Risk analysis : an official publication of the Society for Risk Analysis · 2023Article
- Looking back at prospective modeling of outbreak response strategies for managing global type 2 oral poliovirus vaccine (OPV2) cessation.Frontiers in public health · 2023Review
- Article
- Complexity of options related to restarting oral poliovirus vaccine (OPV) in national immunization programs after OPV cessation.Gates open research · 2023Article
- Health economic analysis of vaccine options for the polio eradication endgame: 2022-2036.Expert review of vaccines · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In early 2020, the COVID-19 pandemic led to substantial disruptions in global activities. The disruptions also included intentional and unintentional reductions in health services, including immunization campaigns against the transmission of wild poliovirus (WPV) and persistent serotype 2 circulating vaccine-derived poliovirus (cVDPV2). Building on a recently updated global poliovirus transmission and Sabin-strain oral poliovirus vaccine (OPV) evolution model, we explored the implications of immunization disruption and restrictions of human interactions (i.e., population mixing) on the expected incidence of polio and on the resulting challenges faced by the Global Polio Eradication Initiative (GPEI). We demonstrate that with some resumption of activities in the fall of 2020 to respond to cVDPV2 outbreaks and full resumption on January 1, 2021 of all polio immunization activities to pre-COVID-19 levels, the GPEI could largely mitigate the impact of COVID-19 to the delays incurred. The relative importance of reduced mixing (leading to potentially decreased incidence) and reduced immunization (leading to potentially increased expected incidence) depends on the timing of the effects. Following resumption of immunization activities, the GPEI will likely face similar barriers to eradication of WPV and elimination of cVDPV2 as before COVID-19. The disruptions from the COVID-19 pandemic may further delay polio eradication due to indirect effects on vaccine and financial resources.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.